Emergent BioSolutions Sees Q2 Sales $170.000M-$185.000M vs $186.000M Est

Benzinga Newsdesk www.benzinga.com Positive 79.0%

Neg 0% Neu 0% Pos 79%

Emergent BioSolutions (NYSE:EBS) sees Q2 sales of $170.000 million-$185.000 million vs $186.000 million analyst estimate.